<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231724</url>
  </required_header>
  <id_info>
    <org_study_id>10-224-A</org_study_id>
    <nct_id>NCT01231724</nct_id>
  </id_info>
  <brief_title>Topical Allstate and Nasal Allergen Challenge</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical Allstate in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (CETALY0001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McNeil Consumer &amp; Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether Allstate Nasal Spray when given in the nose is
      safe and can reduce the signs and symptoms of allergic rhinitis (hayfever).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    study halted prematurely, prior to enrollment of first participant
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">April 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of sneezes and total nasal symptom score (TNSS) (sum of nasal stuffiness, nasal discharge, and nasal itching) (scale 0-3 for each symptom; total score 0-9) are co-primary endpoints.</measure>
    <time_frame>10 minutes following each nasal challenge</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Allstate Nasal Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Nasal Spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Allstate Nasal Spray</intervention_name>
    <description>Allstate Nasal Spray, two sprays (total 100 microliters) in each nostril.</description>
    <arm_group_label>Allstate Nasal Spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Nasal Spray</intervention_name>
    <description>2 sprays in each nostril</description>
    <arm_group_label>Placebo Nasal Spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Males and females between 18 and 55 years of age.

          2. History of grass and/or ragweed allergic rhinitis for at least 2 years.

          3. Positive skin test to grass and/or ragweed antigen within prior 12 months.

          4. Positive response to screening nasal challenge.

        Exclusion Criteria

          1. Respiratory disease other than allergic rhinitis, allergic conjunctivitis and mild
             asthma.

          2. Use of nasal steroids, antihistamines in the last 2 weeks.

          3. Upper respiratory infection, sinusitis less than 2 weeks before screening.

          4. Structural nasal abnormalities or nasal polyps on examination, nasal ulcer, frequent
             nose bleeding, recent nasal surgery or nasal trauma (within 90 days).

          5. Having poorly tolerated previous administration of allergens

          6. Nasolacrimal drainage system malfunctions.

          7. Participation in other investigational therapy in the last 30 days.

          8. Any systemic disorder or medication interfering with the study.

          9. FEV1&lt;80% of predicted at screening for subjects with mild asthma.

         10. Presence of allergic rhinitis symptoms in the screening period with TNSS &gt;3 at
             baseline)

         11. Undergoing allergen desensitization therapy.

         12. Current smokers or recent ex-smokers.

         13. Not willing to give informed consent

         14. Inability to understand the nature and requirements of the study, or to comply with
             the study procedures.

         15. Any social or medical condition that, in the opinion of the investigator, would
             preclude provision of informed consent, make participation in the study unsafe,
             complicate interpretation of study outcome data, or otherwise interfere with achieving
             the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Naclerio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <last_update_submitted>May 30, 2013</last_update_submitted>
  <last_update_submitted_qc>May 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chicago</investigator_affiliation>
    <investigator_full_name>Robert Naclerio</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

